01:43 , Dec 30, 2016 |  BC Week In Review  |  Company News

Triphase, Celgene deal

Triphase granted Celgene an option to acquire all assets relating to lymphoma candidate TRPH-222 (CD22-4AP). If Celgene exercises its option, it will be responsible for development and commercialization of the product, and Triphase will be...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Catalent, Triphase deal

Catalent granted Triphase exclusive, worldwide rights to cancer candidate CD22-4AP. Catalent will receive an upfront payment and is eligible for development and commercialization milestones, plus royalties. The humanized mAb conjugated to a toxin payload...